Stocks surged to one of their biggest gains since World War II after President Donald Trump paused his tariffs against most ...

Within pharma and healthcare ... compared with the “White British” population. These issues are not confined to the UK; in the US, some minority groups including Black, Latino, Pacific ...

Partnership includes training program for medical students, focused on how to analyze clinical trial diversity data ATLANTA, GA – MARCH 31, 2025 – Morehouse School of Medicine (MSM) and the Catalyzing ...

The Easter Bunny is going to ride onboard the train where he will visit with each child, hand out special treats and pose for ...

Leaders at Merck & Co. Inc. are facing a new derivative shareholder lawsuit over allegations that they made misleading ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

We recently published a list of Jim Cramer Recently Talked About These 9 Stocks. In this article, we are going to take a look ...

Goldman Sachs analyst Asad Haider assumed coverage of Merck (MRK) with a Buy rating and price target of $103, down from $129. Following the ...

(Image Source: Pixabay) Even as the pharma sector is still grappling with the uncertainty around the US tariffs, the department of pharmaceuticals (DoP) is planning to get a study done to overhaul ...

The 21st century pharmaceutical and biotech sector has ... the benefit of human health was a comparatively late development. Merck in Germany was possibly the earliest company to move in this ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Merck & Company (MRK – Research ...